A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivoglioblastoma models
Open Access
- 20 July 2009
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 9 (1), 242
- https://doi.org/10.1186/1471-2407-9-242
Abstract
Over the past decades, in spite of intensive search, no significant increase in the survival of patients with glioblastoma has been obtained. The role of the blood-brain barrier (BBB) and especially the activity of efflux pumps belonging to the ATP Binding Cassette (ABC) family may, in part, explain this defect. The in-vitro activities of JAI-51 on cell proliferation were assessed by various experimental approaches in four human and a murine glioblastoma cell lines. Using drug exclusion assays and flow-cytometry, potential inhibitory effects of JAI-51 on P-gp and BCRP were evaluated in sensitive or resistant cell lines. JAI-51 activity on in-vitro microtubule polymerization was assessed by tubulin polymerization assay and direct binding measurements by analytical ultracentrifugation. Finally, a model of C57BL/6 mice bearing subcutaneous GL26 glioblastoma xenografts was used to assess the activity of the title compound in vivo. An HPLC method was designed to detect JAI-51 in the brain and other target organs of the treated animals, as well as in the tumours. In the four human and the murine glioblastoma cell lines tested, 10 μM JAI-51 inhibited proliferation and blocked cells in the M phase of the cell cycle, via its activity as a microtubule depolymerising agent. This ligand binds to tubulin with an association constant of 2 × 105 M-1, overlapping the colchicine binding site. JAI-51 also inhibited the activity of P-gp and BCRP, without being a substrate of these efflux pumps. These in vitro studies were reinforced by our in vivo investigations of C57BL/6 mice bearing GL26 glioblastoma xenografts, in which JAI-51 induced a delay in tumour onset and a tumour growth inhibition, following intraperitoneal administration of 96 mg/kg once a week. In accordance with these results, JAI-51 was detected by HPLC in the tumours of the treated animals. Moreover, JAI-51 was detected in the brain, showing that the molecule is also able to cross the BBB. These in vitro and in vivo data suggest that JAI-51 could be a good candidate for a new treatment of tumours of the CNS. Further investigations are in progress to associate the title compound chemotherapy to radiotherapy in a rat model.Keywords
This publication has 32 references indexed in Scilit:
- Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancersExpert Opinion on Investigational Drugs, 2009
- Caspase-independent cell death: leaving the set without the final cutOncogene, 2008
- Design, synthesis, and biological evaluation of thiophene analogues of chalconesBioorganic & Medicinal Chemistry, 2008
- Caspase-independent mitotic death (CIMD)Cell Cycle, 2008
- Antimitotic and Antiproliferative Activities of Chalcones: Forward Structure–Activity RelationshipJournal of Medicinal Chemistry, 2008
- Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance proteinBioorganic & Medicinal Chemistry, 2008
- Changing Paradigms—An Update on the Multidisciplinary Management of Malignant GliomaThe Oncologist, 2006
- The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in PatientsCancer Research, 2005
- Salvinal, a Novel Microtubule Inhibitor Isolated from Salvia miltiorrhizae Bunge (Danshen), with Antimitotic Activity in Multidrug-Sensitive and -Resistant Human Tumor CellsPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Conformational states of tubulin liganded to colchicine, tropolone methyl ether, and podophyllotoxinBiochemistry, 1982